Table 2.
Clinical profile and laboratory parameters of ALS patients.
| ALS patients Mean ± SD (95% CI) | Males vs. FemalesMann-Whitney U-test | |||
|---|---|---|---|---|
| Total sample | Males | Females | Z (p) | |
| (n = 33) | (n = 21) | (n = 12) | ||
| Clinical profile | ||||
| Spinal/bulbar | 22/11 | 15/6 | 7/5 | |
| Duration of symptoms (months) | 24.1 ± 17.8 (17.5–30.6) | 28.1 ± 19.6 (18.9–37.3) | 16.9 ± 11.4 (9.1–24.5) | −1.514 (0.130) |
| ALSFRS-R score | 34.9 ± 8.8 (31.3–38.4) | 34.4 ± 10.1 (20.3–39.4) | 36.1 ± 5.2 (31.7–40.5) | −0.056 (0.978) |
| Barthel index | 75.3 ± 22.9 (63.8–86.7) | 79.1 ± 24.0 (63.9–94.4) | 67.5 ± 20.4 (46.0–88.9) | −1.100 (0.271) |
| FEV% | 77.0 ± 13.9 (68.9–85.0) | 80.3 ± 13.2 (70.8–89.7) | 68.7 ± 13.5 (47.4–90.3) | −1.346 (0.178) |
| Fat% | 18.2 ± 3.8 (16.4–19.9) | 16.9 ± 2.8 (15.4–18.5) | 21.1 ± 4.8 (16.1–26.1) | −2.258 (0.024)* |
| Muscle% | 36.8 ± 3.1 (32.2–40.6) | 37.0 ± 2.8 (35.4–38.3) | 36.4 ± 3.9 (32.2–40.6) | −0.467 (0.640) |
| MRC global score | 58.2 ± 16.4 (50.7–65.7) | 59.6 ± 17.0 (49.7–69.3) | 55.6 ± 16.0 (40.7–70.3) | −0.674 (0.500) |
| Laboratory parameters | ||||
| 25-OH-Vit D (ng/mL) | 21.8 ± 7.8 (15.8–27.8) | 22.5 ± 7.3 (15.6–29.3) | 19.5 ± 12.1 (9.1–28.2) | −0.586 (0.558) |
| Calcium (mg/dL) | 9.4 ± 0.3 (9.2–9.6) | 9.5 ± 0.2 (9.3–9.6) | 9.3 ± 0.5 (8.5–10.1) | −0.568 (0.570) |
| Alkaline phosphatase UI/L | 64.3 ± 21.1 (54.4–74.1) | 65.1 ± 22.3 (52.7–77.5) | 61.8 ± 18.7 (38.5–85.1) | −0.087 0.930 |
| T4 (ng/dL) | 1.9 ± 2.3 (0.45–3.4) | 1.1 ± 0.2 (0.9–1.2) | 3.3 ± 3.60 (−2.4–9.1) | −2.457 (0.014)* |
| TSH (uU/mL) | 1.6 ± 0.6 (1.3–1.9) | 1.7 ± 0.5 (1.3–1.9) | 1.5 ± 0.8 (0.8–2.3) | −0.463 (0.663) |
*
p < 0.05.